Biological Characteristics of Older Women (> 70 Years) With ER Positive, HER2 Negative Early Breast Cancer

NCT05734950 | Unknown

• 1 other identifier: CCR5654
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

This study is investigating the biological characteristics of early oestrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) in older woman (aged \> 70 years) who were treated with adjuvant endocrine treatment (ET). It will use surgical tissue previously collected as part of routine care from patients aged 70 years or older at diagnosis with ER positive, HER2 negative stage I-III BC treated The Royal Marsden NHS Foundation Trust (RMH). The overarching aim of this study is to define the biological characteristics of early BC in older women in terms of tumour microenvironment (TME), molecular and genomic features. This analysis will include assessment of tumour infiltrating lymphocytes (TILs), and gene expression profiling with NanoString using the Breast Cancer 360 (BC360TM) assay measuring ribonucleic acid (RNA) expression signatures of genes involved in proliferation, endothelial, angiogenesis, cytotoxicity, stroma, inflammatory chemokines, and apoptosis. This analysis will examine various biological pathways, aiming to inform suitability for certain treatments including cyclin-dependent kinase inhibitors (CDKi), chemotherapy, immunotherapy, or targeted treatments such as phosphoinositide 3-kinases (PI3K) inhibitors, or deoxyribonucleic acid (DNA) damage response.

Conditions

Breast Cancer Female

Outcome Measures

Primary Outcomes (1)

• Distribution of TILs percentage

  assessed via immunohistochemistry

  August 2023

Secondary Outcomes (2)

• Gene expression profile patterns across the cohort.

  August 2023

• Relationship between PAM50, Ki67 (<10% low, ≥ 10% high), PD-L1, modified AIR-CIS

  August 2023

Other Outcomes (1)

• Association of the molecular features with TTR (Defined as the time from diagnosis (initial biopsy) to local, regional, or distant tumour recurrence or death from breast cancer without prior notification of relapse.).

  August 2023

Interventions

Translational study OTHER

Non-interventional, translational study

Eligibility Criteria

• Age: 71 Years+
• Healthy Volunteers: Yes
• Age Groups: Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This is a non-interventional, translational study, using surgical tissue (collected as part of routine care) from older women (aged \> 70 years at the time of diagnosis) with early (stage I-III), ER positive, HER2 negative BC who were treated curatively with primary surgery. Patients would not have had any prior treatment with (neo-) adjuvant chemotherapy but received an aromatase-inhibitor in the adjuvant setting.

You may qualify if:

• Post-menopausal women aged \>70 years at the time of diagnosis of invasive breast cancer.
• ER positive (Allred score \>5/8), HER2 negative early invasive BC.
• Stage I-III BC.
• Surgical tissue available.
• No pre-surgical systemic therapy (i.e., no pre-operative ET or chemotherapy).
• Planned adjuvant ET with an aromatase-inhibitor.
• No adjuvant chemotherapy.
• Surgery was performed between 1st January 2014 and 31st December 2016.

You may not qualify if:

• Pre- or perimenopausal.
• ER negative or HER2-positive BC.
• Multifocal cancer where not all of foci ER positive HER2 negative
• Bilateral breast cancer.
• Stage IV breast cancer.
• Benign histology or DCIS.
• Pre-surgical treatment.
• Prior chemotherapy for BC.

Sponsors & Collaborators

• Royal Marsden NHS Foundation Trust: lead
• Institute of Cancer Research, United Kingdom: collaborator
• National Institute for Health Research, United Kingdom: collaborator

Study Sites (1)

The Royal Marsden NHS Foundation Trust

Sutton, SM2 5PT, United Kingdom

Location

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 8, 2023
• First Posted: February 21, 2023
• Study Start: July 21, 2022
• Primary Completion: August 31, 2023
• Study Completion: August 31, 2023
• Last Updated: February 21, 2023

Record last verified: 2023-02

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)